292 related articles for article (PubMed ID: 35652285)
1. TAR DNA-binding protein of 43 kDa (TDP-43) and amyotrophic lateral sclerosis (ALS): a promising therapeutic target.
Ojaimi YA; Dangoumau A; Alarcan H; Hergesheimer R; Vourc'h P; Corcia P; Lanznaster D; Blasco H
Expert Opin Ther Targets; 2022 Jun; 26(6):575-592. PubMed ID: 35652285
[TBL] [Abstract][Full Text] [Related]
2. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis.
Suk TR; Rousseaux MWC
Mol Neurodegener; 2020 Aug; 15(1):45. PubMed ID: 32799899
[TBL] [Abstract][Full Text] [Related]
3. TDP-43 Proteinopathy and ALS: Insights into Disease Mechanisms and Therapeutic Targets.
Scotter EL; Chen HJ; Shaw CE
Neurotherapeutics; 2015 Apr; 12(2):352-63. PubMed ID: 25652699
[TBL] [Abstract][Full Text] [Related]
4. Pathological mechanisms underlying TDP-43 driven neurodegeneration in FTLD-ALS spectrum disorders.
Janssens J; Van Broeckhoven C
Hum Mol Genet; 2013 Oct; 22(R1):R77-87. PubMed ID: 23900071
[TBL] [Abstract][Full Text] [Related]
5. Disease animal models of TDP-43 proteinopathy and their pre-clinical applications.
Liu YC; Chiang PM; Tsai KJ
Int J Mol Sci; 2013 Oct; 14(10):20079-111. PubMed ID: 24113586
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.
Wood A; Gurfinkel Y; Polain N; Lamont W; Lyn Rea S
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946763
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-183-5p regulates TAR DNA-binding protein 43 neurotoxicity via SQSTM1/p62 in amyotrophic lateral sclerosis.
Kim HC; Zhang Y; King PH; Lu L
J Neurochem; 2023 Mar; 164(5):643-657. PubMed ID: 36527420
[TBL] [Abstract][Full Text] [Related]
8. TDP-43 pathology: From noxious assembly to therapeutic removal.
Keating SS; San Gil R; Swanson MEV; Scotter EL; Walker AK
Prog Neurobiol; 2022 Apr; 211():102229. PubMed ID: 35101542
[TBL] [Abstract][Full Text] [Related]
9. Nuclear import receptors are recruited by FG-nucleoporins to rescue hallmarks of TDP-43 proteinopathy.
Khalil B; Chhangani D; Wren MC; Smith CL; Lee JH; Li X; Puttinger C; Tsai CW; Fortin G; Morderer D; Gao J; Liu F; Lim CK; Chen J; Chou CC; Croft CL; Gleixner AM; Donnelly CJ; Golde TE; Petrucelli L; Oskarsson B; Dickson DW; Zhang K; Shorter J; Yoshimura SH; Barmada SJ; Rincon-Limas DE; Rossoll W
Mol Neurodegener; 2022 Dec; 17(1):80. PubMed ID: 36482422
[TBL] [Abstract][Full Text] [Related]
10. PABPN1 suppresses TDP-43 toxicity in ALS disease models.
Chou CC; Alexeeva OM; Yamada S; Pribadi A; Zhang Y; Mo B; Williams KR; Zarnescu DC; Rossoll W
Hum Mol Genet; 2015 Sep; 24(18):5154-73. PubMed ID: 26130692
[TBL] [Abstract][Full Text] [Related]
11. TDP-43 proteinopathy and mitochondrial abnormalities in neurodegeneration.
Gao J; Wang L; Yan T; Perry G; Wang X
Mol Cell Neurosci; 2019 Oct; 100():103396. PubMed ID: 31445085
[TBL] [Abstract][Full Text] [Related]
12. Defective cyclophilin A induces TDP-43 proteinopathy: implications for amyotrophic lateral sclerosis and frontotemporal dementia.
Pasetto L; Grassano M; Pozzi S; Luotti S; Sammali E; Migazzi A; Basso M; Spagnolli G; Biasini E; Micotti E; Cerovic M; Carli M; Forloni G; De Marco G; Manera U; Moglia C; Mora G; Traynor BJ; Chiò A; Calvo A; Bonetto V
Brain; 2021 Dec; 144(12):3710-3726. PubMed ID: 34972208
[TBL] [Abstract][Full Text] [Related]
13. Emerging Therapies and Novel Targets for TDP-43 Proteinopathy in ALS/FTD.
Hayes LR; Kalab P
Neurotherapeutics; 2022 Jul; 19(4):1061-1084. PubMed ID: 35790708
[TBL] [Abstract][Full Text] [Related]
14. The Role of TDP-43 in Neurodegenerative Disease.
Liao YZ; Ma J; Dou JZ
Mol Neurobiol; 2022 Jul; 59(7):4223-4241. PubMed ID: 35499795
[TBL] [Abstract][Full Text] [Related]
15. Aggregation of the nucleic acid-binding protein TDP-43 occurs via distinct routes that are coordinated with stress granule formation.
Chen Y; Cohen TJ
J Biol Chem; 2019 Mar; 294(10):3696-3706. PubMed ID: 30630951
[TBL] [Abstract][Full Text] [Related]
16. [Neuropathology of TDP-43 proteinopathy].
Akiyama H; Hasegawa M
Brain Nerve; 2013 Dec; 65(12):1477-89. PubMed ID: 24323933
[TBL] [Abstract][Full Text] [Related]
17. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD.
Kumar S; Phaneuf D; Cordeau P; Boutej H; Kriz J; Julien JP
Mol Neurodegener; 2021 Jan; 16(1):1. PubMed ID: 33413517
[TBL] [Abstract][Full Text] [Related]
18. "STRESSED OUT": The role of FUS and TDP-43 in amyotrophic lateral sclerosis.
Aksoy YA; Deng W; Stoddart J; Chung R; Guillemin G; Cole NJ; Neely GG; Hesselson D
Int J Biochem Cell Biol; 2020 Sep; 126():105821. PubMed ID: 32758633
[TBL] [Abstract][Full Text] [Related]
19.
Cook CN; Wu Y; Odeh HM; Gendron TF; Jansen-West K; Del Rosso G; Yue M; Jiang P; Gomes E; Tong J; Daughrity LM; Avendano NM; Castanedes-Casey M; Shao W; Oskarsson B; Tomassy GS; McCampbell A; Rigo F; Dickson DW; Shorter J; Zhang YJ; Petrucelli L
Sci Transl Med; 2020 Sep; 12(559):. PubMed ID: 32878979
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 mice.
Becker LA; Huang B; Bieri G; Ma R; Knowles DA; Jafar-Nejad P; Messing J; Kim HJ; Soriano A; Auburger G; Pulst SM; Taylor JP; Rigo F; Gitler AD
Nature; 2017 Apr; 544(7650):367-371. PubMed ID: 28405022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
